论文部分内容阅读
自从1963年Sodi-Pallares氏介绍用GIK(葡萄糖—胰岛素—钾盐)溶液静脉输入以降低急性心肌梗塞病人的死亡率以来,GIK溶液已被广泛用于心肌的新陈代谢的支持疗法。这种溶液的疗效和可能的治疗机制仍有争论。在心肌梗塞的早期用GIK溶液是有益处的,可能由于它能使血浆中原来升高的游离脂肪酸(FFA)浓度降低,甚至降到正常水平以下(<350uEq/升)之故。在急性心肌梗塞时(FFA一般超过正常浓度,因而增加了心室的兴奋性,
Since Sodi-Pallares’ introduction of intravenous infusion of a solution of GIK (Glucose-Insulin-Potassium) in 1963 to reduce mortality in patients with acute myocardial infarction, GIK solutions have been widely used in cardiomyopathic supportive therapies. The efficacy of this solution and possible therapeutic mechanisms remain controversial. It is beneficial to use GIK at an early stage of myocardial infarction, probably because it decreases the original elevated free fatty acid (FFA) concentration in plasma even below normal levels (<350uEq / liter). In acute myocardial infarction (FFA generally exceeds the normal concentration, thus increasing the excitability of the ventricle,